Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.

被引：1
|
作者：
Wang, Yan
Yang, Guangjian
Li, Jun
Xu, Haiyan
Yang, Lu
Xu, Fei
Yang, Yaning
Xia, Bing
Zhu, Viola Weijia
Qiu, Weini
Ou, Sai-Hong Ignatius
机构：
[1] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Ctr Clin Lab Med, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Dept Comprehens Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[6] USC Norris Cance Ctr, Los Angeles, CA USA
[7] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Orange, CA 92668 USA
[8] Healthy, Beijing, Peoples R China
[9] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9043
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of sunvozertinib in treatment naive NSCLC patients with EGFR exon20 insertion mutations
    Xu, Yan
    Yang, James Chih-Hsin
    Chiu, Chao-Hua
    Hsu, Ping-Chih
    Mitchell, Paul
    Chang, Chia Lun
    John, Tom
    Bazhenova, Lyudmila
    Kim, Tae Min
    Yip, Ching Wan
    Wang, Mengzhao
    Janne, Pasi A.
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
    Yang, J. C-H.
    Wang, M.
    Chiu, C-H.
    Hsu, P-C.
    Mitchell, P.
    Chang, C. L.
    Kim, T. M.
    John, T.
    Greillier, L.
    Bazhenova, L.
    Carcereny, E.
    Spira, A. I.
    Shim, B.
    Lee, K. H.
    Cobo Dols, M.
    Ghiringhelli, F.
    Yip, C. W.
    Xiong, J.
    Janne, P. A.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [33] Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC
    Angela Zupa
    Giulia Vita
    Matteo Landriscina
    Luciana Possidente
    Michele Aieta
    Alfredo Tartarone
    Giuseppina Improta
    Medical Oncology, 2012, 29 : 3198 - 3201
  • [34] Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC
    Zupa, Angela
    Vita, Giulia
    Landriscina, Matteo
    Possidente, Luciana
    Aieta, Michele
    Tartarone, Alfredo
    Improta, Giuseppina
    MEDICAL ONCOLOGY, 2012, 29 (05) : 3198 - 3201
  • [35] Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC
    Ou, Sai-Hong Ignatius
    Hong, Jin-Liern
    Christopoulos, Petros
    Lin, Huamao M.
    Vincent, Sylvie
    Churchill, Eric N.
    Soeda, Junpei
    Kazdal, Daniel
    Stenzinger, Albrecht
    Thomas, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (06) : 744 - 754
  • [36] Clinicopathological Characteristics for NSCLC Harboring EGFR Exon 20 Insertion
    Morikawa, K.
    Kakinuma, K.
    Inoue, T.
    Mineshita, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S496 - S496
  • [37] Real-world treatment patterns and clinical outcomes in EGFR-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients.
    Bi, Nan
    Wang, Luhua
    Xu, Kunpeng
    Ge, Hong
    Mingyan, E.
    Zhang, Li
    Cao, Jianzhong
    Zhang, Xu
    Xia, Bing
    Zhao, Lujun
    Li, Jiancheng
    Hu, Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.
    Chouaid, Christos
    Filleron, Thomas
    Debieuvre, Didier
    Perol, Maurice
    Girard, Nicolas
    Dansin, Eric
    Gervais, Radj
    Cousin, Sophie
    Otto, Josiane
    Schott, Roland
    Planchard, David
    Madroszyk, Anne
    Kaderbhai, Coureche
    Dubray-Longeras, Pascale
    Hiret, Sandrine
    Pichon, Eric
    Clement-Duchene, Christelle Anne
    Martin, Anne-Laure
    Simon, Gaetane
    Quantin, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
    Sabari, J.
    Kim, T. M.
    Spira, A.
    Lee, S. H.
    Chang, G. C.
    Shih, J. -Y.
    Hochmair, M. J.
    Schioppa, C. A.
    Schioppa, C. A.
    Panaccione, A.
    Rose, J. B.
    Chioda, M.
    Mahadevia, P.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E23 - E23
  • [40] Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
    Kim, T. M.
    Lee, S-H.
    Chang, G-C.
    Shih, J-Y.
    Hochmair, M. J.
    Sabari, J. K.
    Spira, A. I.
    Schioppa, C. A.
    Rose, J. B.
    Chioda, M.
    Panaccione, A.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S48 - S48
12345